February / March #89 : Sore Winner? - by Anita Flanagan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Rapid Test Time

The Love Cure

Date Bait

Make It Last Forever

To Die For

A Gallo Gotcha

Neg & Pos

That '70s Show

Tribute: Tom Fahey



Heavy Medals

Sign Of The Times

Thief of HAARTs

Shine Some Light

Hokey Pokey

AIDS Acts Axed

Good China

Copay Through The Nose


Sore Winner?

Blame Candida

I Get Misty

Female Troubles

Fellow Travelers

Reality Check


America's Sweetheart

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

February / March 2003

Sore Winner?

by Anita Flanagan

File this under "No Biggie for HIVers but Potential Badda-boom for their Sex Partners": Researchers at GlaxoSmithKline (GSK) grabbed front-page headlines last November when they announced they were desperately seeking Susans to test a vaccine against genital herpes (HSV-2), a bug that has bitten some 50 million Americans (and counting, at the rate of a million a year). It's no news for HIVers because the vast majority already have herpes, but it could mean a lot for their sweeties who are HIV and HSV negative. Why? Because herpes is easily spread -- even absent open sores, and, alas, even if you use a condom (the glove may not cover all affected areas). Plus, it facilitates transmission of HIV.

Vax-maker GSK announced it was launching the trial after a University of Texas study of 2,700 HSV neggies showed that the formula had fought off infection in three-quarters of the women. Sad to report, it fared poorly in gals already infected with the related HSV-1; even more strange, it was a total flop in guys. GSK will recruit about 7,550 women for sites nationwide. If results resemble those in the Texas study, the vax could hit the market in about five years -- a mere blip on the vax-research timeline. For info on how to sign up, visit www.niaid.nih.gov/dmid/stds/herpevac. Last but not least, whether the vax will have a therapeutic benefit for HSV positives remains to be seen.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.